DUBLIN, January 21, 2021 / PRNewswire / – Supportive Care in Cancer – Comprehensive Review, Pipeline Products, Research and Development Strategies, and Unmet Needs report has been added to ResearchAndMarkets.com’s offering.

The report uses survey-based data and KOL insights to provide a comprehensive overview of a number of issues, including current treatment options used for various indications within SCC and treatment guidelines that are followed for those indications. With regard to clinical development, pipeline products and R&D strategies for individual indications are addressed. The report also looks at some of the clinical trial challenges that arise in this area and provides an overview of the unmet needs that exist for various SCC indications.

Supportive care for cancer is an evolving discipline of medicine that is critical to holistic management of cancer patients. With significant advances in the treatment of cancer, particularly through the development of immuno-oncology (IO) and targeted therapies, it is equally important to focus on supportive care for cancer to ensure that patients complete the treatment cycle for cancer treatment can primary cancer as well as improve their quality of life.

Key highlights

  • Advances in understanding disease mechanisms, coupled with therapeutic advances in some SCC indications, should raise awareness in this area.
  • Although considerable therapeutic advances have been achieved for some SCC indications, the analysis of the overall field shows that there are differences with regard to the current treatment options, especially in indications for which no approved therapies exist.
  • The breadth of pipeline products in clinical development is encouraging for SCC, especially for indications that are currently underserved in terms of approved therapies.
  • The presence of both clinical and environmental needs within the SCC space enables pharmaceutical companies and policy makers to participate in the development of effective therapeutics and frameworks to further advance the field. Therapies that can bring significant benefit to patients, especially with regard to improving the quality of life and the regulatory framework that can facilitate counseling, especially for some SCC indications, are of particular importance in closing the existing gap.

Key questions answered

  • What treatment guidelines and treatment options are used by oncologists in the 7MM for different indications within SCC?
  • What is the current status of SCC, particularly with regards to the attitudes of the doctor, and how is this trend likely to change in the future? What effects do newer active ingredients such as IO and targeted therapies have on the SCC area?
  • What different R&D strategies are pharmaceutical companies pursuing within individual indications as part of SCC? What are the challenges associated with clinical trials in this area?
  • What are the currently unmet needs and what steps are being taken to fill these gaps in the SCC?

Main topics covered:

1 Introduction

2. Summary
2.1. Main results

3. Supportive care in the cancer overview
3.1. What is supportive care for cancer?

4. Epidemiology
4.1. Diagnosed cases of cancer in 2019
4.2. Diagnosed cases of cancer receiving chemotherapy
4.3. Diagnosed cases of cancer receiving chemotherapy with disease
4.4. Five years of diagnosed prevalence cases of all cancers

5. Current and future status of treatment guidelines
5.1. Treatment Guidelines for Different Indications in Supportive Cancer Treatment – Survey Results
5.2. Reasons for Failure to Follow Treatment Guidelines – KOL Opinion
5.3. Commonly used treatment guidelines for indications in the supportive treatment of cancer
5.4. Current State of Supportive Care in Cancer – KOL Opinion
5.5. Attitude of the doctor to supportive treatment of cancer – KOL Opinion
5.6. Future Prospects for Supportive Cancer Treatment – KOL Opinion
5.7. Influence of immuno-oncological therapies and targeted therapies on the SCC – KOL opinion
5.8. The role of immuno-oncological therapies and targeted therapies in the creation of new side effect profiles – KOL Opinion

6. Current treatment options
6.1. Important MOAs for various indications in the supportive treatment of cancer
6.2. Important marketed product information for various indications in the supportive treatment of cancer
6.3. Commonly Used Marketed Products for Various Indications in Supportive Cancer Treatment – Survey Results
6.4. Satisfaction with marketed products for various indications as part of the supportive cancer treatment – survey
Results
6.5. Marketed products for various indications as part of the supportive treatment of cancer – KOL perspective

7. Pipeline products and R&D strategies
7.1. Awareness and potential for R&D strategies for various indications within the framework of supportive cancer treatment –
Survey results
7.2. Pipeline products for various indications in the supportive treatment of cancer – KOL Opinion

8. Clinical Trial Design and Challenges
8.1. Clinical Trial Challenges and Endpoints for Various Indications in Supportive Cancer Treatment – Survey Results
8.2. Challenges and endpoints of clinical trials for different indications in the supportive treatment of cancer – KOL Opinion

9. Unsatisfied needs and opportunities
9.1. Important unmet need for various indications in the supportive treatment of cancer
9.2. Significance level of unmet need for various indications in supportive treatment of cancer – survey results
9.3. Unsatisfied need for various indications in the supportive treatment of cancer – KOL Opinion

10. Appendix

Mentioned companies

  • AbbVie
  • Ratiopharm
  • Amgen
  • Asahi Kasei Pharma Corp.
  • AstraZeneca
  • Bayer Healthcare
  • Benuvia Therapeutics
  • BetterLife Pharma
  • BeyondSpring
  • BristolMyers Squibb
  • Chugai Pharmaceutical
  • Daichii Sankyo
  • Dauntless Pharmaceuticals Inc.
  • Helsinn Group
  • Heron Therapeutics
  • Immunopharmaceuticals
  • Janssen-Cilag
  • Kyowa Kirin
  • LTL Pharma
  • Medice Medicinal Putter
  • MediciNova
  • Merck
  • Mirati Therapeutics
  • Mundipharma International Ltd.
  • Mylan Pharmaceuticals
  • Napo Pharmaceuticals
  • Novartis
  • Ono Pharmaceutical
  • Partner Therapeutics
  • Pfizer
  • PHD Biosciences
  • Q BioMed
  • Ratiopharm
  • Relypsa
  • Roche
  • Rottapharm
  • Sandoz
  • Spaces
  • Spectrum Pharmaceuticals
  • Stada Medicines
  • Taiho Pharmaceutical Co Ltd.
  • TerSera Therapeutics
  • Teva Pharmaceuticals
  • Torii Pharmaceutical
  • WEX Pharmaceuticals Inc.

Please visit https://www.researchandmarkets.com/r/bzvbz0 for more information on this report

Research and Markets also offers custom research services that provide focused, comprehensive, and bespoke research.

Media contact:

Research and Markets
Laura Wood, Senior manager
[email protected]

For EST office hours, call + 1-917-300-0470
For US / CAN, call toll-free at 800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716

SOURCE RESEARCH and Markets

similar links

http://www.researchandmarkets.com